PMC:7554011 / 26411-26957 JSONTXT

{"target":"http://pubannotation.org/docs/sourcedb/PMC/sourceid/7554011","sourcedb":"PMC","sourceid":"7554011","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7554011","text":"Ratio (%) between each AUC0–4 h in vitro and AUC0–4 h in vivo (AUC0–4 h in vitro/AUC0–4 h in vivo × 100). AUC0–4 h in vitro: a in vitro fasted-state gastric followed by fasted-state intestinal conditions; and b in vitro fasted-state gastric followed by fed-state intestinal conditions. AUC0–4 h in vivo: calculated from the absorption profiles after deconvolution of the in vivo plasma profiles of Singulair® granules (4 mg) in infants (16,17,19); (grey area represents the range criteria (80–125%) set for prediction of in vivo drug performance)","tracks":[{"project":"2_test","denotations":[{"id":"33051713-16707408-26822","span":{"begin":437,"end":439},"obj":"16707408"},{"id":"33051713-18296556-26823","span":{"begin":440,"end":442},"obj":"18296556"},{"id":"33051713-15102869-26824","span":{"begin":443,"end":445},"obj":"15102869"}],"attributes":[{"subj":"33051713-16707408-26822","pred":"source","obj":"2_test"},{"subj":"33051713-18296556-26823","pred":"source","obj":"2_test"},{"subj":"33051713-15102869-26824","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"2_test","color":"#ec93c9","default":true}]}]}}